The purpose of this study is to investigate whether naltrexone reduces the intensity and duration of flashbacks and dissociative states in patients with borderline personality disorder.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
48
Daily oral administration (capsules): 50mg naltrexone and placebo or 200mg naltrexone and placebo or placebo and naltrexon 50mg or placebo and 200mg naltrexone
Dept. of Psychosomatic Medicine, Central Instiute of Mental Health
Mannheim, Baden-Würtemberg, Germany
Klinik Dr. Schlemmer GmbH, Center for Psychosomatic Medicine
Bad Wiessee, Bavaria, Germany
Inntalklinik Simbach am Inn
Simbach, Bavaria, Germany
Dept.of Psychiatry and Psychotherapy; Center of Neurology
Rostock, Mecklenburg-Vorpommern, Germany
Reduction of dissociative symptoms
Time frame: End of 3rd week treatment of naltrexon
Reduction of flashbacks
Time frame: End of 3rd week treatment of naltrexone
Reduction of self-injurious behavior
Time frame: End of 3rd week treatment of naltrexone
Reduction of psychopathology (depression, anxiety, anger, borderline symptoms)
Time frame: End of 3rd week treatment of naltrexone
Safety regarding liver enzyme elevation
Time frame: End of 3rd week treatment of naltrexone
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Dept.of Psychiatry and Psychotherapy , Rheinische Kliniken Köln
Cologne, North Rhine-Westphalia, Germany